
    
      This is a randomized, double-blind, placebo-controlled Phase 2 study of MM-141 plus
      nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine in front-line
      metastatic pancreatic cancer. All patients will be initially screened for free IGF-1 status.
      Eligible patients with high free IGF-1 will be randomized to receive MM-141 plus
      nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine and patients.
      Patients with low free IGF-1 or patients who have high free IGF-1 but are not otherwise
      eligible will be followed in an observational group.
    
  